Overview

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer

Status:
Recruiting
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer. The main questions it aims to answer are: - prognostic value of baseline MRD; - the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before conversion therapy initiation and at the first imaging assessment after chemotherapy.
Phase:
N/A
Details
Lead Sponsor:
Peking Union Medical College Hospital